<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122789">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027272</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0269</org_study_id>
    <nct_id>NCT02027272</nct_id>
  </id_info>
  <brief_title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):</brief_title>
  <acronym>PRESIDEX</acronym>
  <official_title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more
      quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome
      (PRES) encountered in eclamptic patients.  All patients regardless of assignment to placebo
      or steroid will receive standard therapy to include magnesium sulfate, blood pressure
      medications and diuretics.  We hypothesize that the addition of dexamethasone to standard
      therapy will accelerate CNS recovery more quickly than standard management without
      dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 eclamptic patients who do not require steroids for fetal lung maturation purposes will be
      randomized to placebo or steroid.  This includes patients with eclampsia encountered
      antepartum prior to 23 weeks gestation, postpartum eclampsia, undelivered patients
      encountered after 33 weeks gestation who would not be candidates for fetal lung maturation
      steroids, or patients not eligible for repeat steroid administration in the 23-34 week
      gestational window.  Planned enrollment in this pilot study is up to 30 patients with at
      least 12 in each group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting, only one participant in 18 months, rarity of event
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized clinical trial evaluating corticosteroid efficacy to augment standard therapy and shorten recovery</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To learn if giving IV dexamethasone to eclamptic women with PRES will accelerate normalization of CNS function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Eclampsia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 doses, 12 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Potent glucocorticoid or steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Currently 34 weeks pregnant or within 6 weeks postpartum

          2. At least 18 years of age

          3. Singleton or twin gestation

          4. Patient or family sign informed consent

          5. Diagnosis of eclampsia

          6. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure

        Exclusion Criteria:

          1. Neither pregnant nor within first 6 weeks postpartum

          2. Patient or family unable to sign informed consent

          3. Less than 18 years of age

          4. Triplet or higher order gestation

          5. Unable to obtain MRI scanning within 24 hours of hospital admission (

          6. Diagnosis of cerebral hemorrhage

          7. Patient in whom MRI is contraindicated
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medican Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>James Martin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Eclampsia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Posterior Leukoencephalopathy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
